Increasing preference for precision medicine will remain a key factor propelling research and commercialization in the RNA transcriptome profiling test market in the near future.
Increasing preference for precision medicine will remain a key factor propelling research and commercialization in the RNA transcriptome profiling test market in the near future.
Fact.MR Rockville, MD: Market research company Fact.MR’s ongoing RNA transcriptome profiling test market study has estimated strong growth in 2021 and beyond, driven by increased emphasis being placed on personalized medicine and cancer research. The covid-19 pandemic has largely left the industry unaffected owing to efforts in novel drug development targets.
According to the National Library of Medicine, patients can display substantial heterogeneous outcomes to treatment. Consequently, ideal strategies for treatment will display requirements for the adaptation as per the individual. Recently months have displayed the introduction of numerous new statistical methods to handle the crucial challenge of estimating personalized treatment guidelines with the aid of using single or multiple-stage clinical data.
The use of RNA transcriptome profiling tests allow for improved understanding of molecular pathology of diseases owing to genomic studies, which facilitate the development of treatments that target discrete molecular subclasses of tumors. These factors will play significant roles in the future of the market.
“Frequent upgrades to technology, the use of robust methodologies, increased preference for more compact products are key factors driving the RNA transcriptome profiling test market. Further, improvements to automation of transcriptome analysis methods and applications in analyzing gene expression will widen the scope of application and uptake,” says the Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=3113
Key Takeaways
- Nucleic acid amplification and SAGE analysis methods are likely to witness increased adoption owing to automation benefits
- Next generation sequencing technology contributes to demand for RNA and targeted resequencing applications
- Biotechnology and pharmaceutical sector applications will create opportunities
- Significant investments towards research & development and growing awareness boost adoption in US
- UK and Germany will reflect strong growth on the back of research initiatives for rare inherited diseases and cancer treatment
- RNA sequencing research investments in India and China reflect high growth potential.
Prominent Drivers
- Growing preference for personalized medicine among patients and drug manufacturers is driving market developments.
- Frequent tech advancements in genomics, transcriptomics, and proteomics towards cancer research generates growth opportunities.
- Growing awareness about the role of carcinogens in terms of genetic mutations in the healthcare sector will support growth.
Key Restraints
- High costs and maintenance requirements for sequencing platforms is a major challenge for market players.
- Lack of awareness, infrastructure, and skilled professionals particularly in developing economies is expected to hold back market growth.
Discover more about the RNA transcriptome profiling test market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/3113/rna-transcriptome-profiling-test-market
Competitive Landscape
Merck KGaA, Affymetrix, Promega Corporation, Agilent Technologies Inc., General Electric Company, Life Technologies, F. Hoffmann-La Roche Ltd., Qiagen N.V., and Bio-Rad Laboratories, Inc., are some of the leading players operating in the global RNA transcriptome profiling test market.
Key players in the RNA transcriptome profiling test market are displaying interest in strategic collaborations within the industry aimed towards consolidating market position through research and development endeavors.
In March 2021, Strata Oncology Inc. announced the launch of Strata Precision Indications for Approved Therapies, or “Strata PATH,” trial in collaboration with Pfizer Inc, for multi-drug, multi-arm bio-marker driven clinical trials including genomic and transcriptomic data.
Caris Life Sciences has announced the inclusion of the Moores Cancer Center at UC San Diego Health to the Caris’ Precision Oncology Alliance – a network of leading cancer centers for genomic, transcriptomic and proteomic cancer profiling and molecular testing endeavors.
More Insights on the RNA Transcriptome Profiling Test Market
In its latest report, Fact.MR offers unbiased analysis of the global RNA transcriptome profiling test market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of component type [consumables (reagents, kits, and dyes), instruments (RT PCR, Microarray, Sanger Sequencing Platform, RNA Sequencing Platform), software and services] method type [conventional methods (RNA-DNA hybridization measurements, subtractive hybridization, and differential display) high throughput methods(hybridization-based method using Micro Array Technology and sequence based – RNA sequencing, serial analysis of gene expression, massively parallel signature sequencing)], application (cancer research, complex disease biomarker identification, agrigenomics, RNA-based drug response biomarker discovery, and others), and end user (hospital based laboratories, diagnostic centers, academic and research institutes, contract research organizations, and others) across five regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa)
Request more information about Report Table of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=3113
Explore Fact.MR’s Coverage on the Healthcare Domain
Colored Contact Lenses Market: A recent study by Fact.MR on the colored contact lenses market offers a 8-year forecast for 2018 to 2026. The study analyzes key trends that are currently determining the growth of the market. This report covers vital dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.
High-Sensitivity Cardiac Biomarker Market: Fact.MR’s extensive coverage on the high-sensitivity cardiac biomarker market offers in-depth insights about the prominent growth dynamics that are likely to aid expansion of prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the landscape.
Acromegaly Treatment Market: The global acromegaly treatment market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in forthcoming years.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Sudip Saha
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583